Larotrectinib (Vitrakvi®) is indicated for patients with solid tumours that display a Neurotrophic Tyrosine Receptor Kinase (NTRK) gene fusion.
|NCPE Assessment Process||Ongoing|
|Rapid review commissioned||20/11/2019|
|Rapid review completed||13/01/2020|
|Rapid Review outcome||A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of larotrectinib compared with the current standard of care.|